MicroRNAs with prognostic significance in osteosarcoma: a systemic review and meta-analysis

Cheng, Dong; Qiu, Xubin; Zhou, Ming; Zhu, Caiying; Zou, Hongjun; Liu, Zhiwei

doi:10.18632/oncotarget.19009

Cited by 24 publications

(23 citation statements)

References 75 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Downregulation of plasma miR-124 expression was a predictive biomarker for prognosis of glioma [10,22]. A large number of previous studies have suggested that miR-124 could be used as a molecular marker for tumor progression in cervical cancer [23,24], breast cancer [12,25,26], lung cancer [27,28], and osteosarcoma [29]. Numerous clinical studies have shown that BRCA is the most common type of breast cancer and has poor prognosis survival, and the pathogenesis of breast cancer involves a variety of factors and genes [4,30].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the Role of hsa-mir-124 in Predicting Clinical Outcome in Breast Invasive Carcinoma Based on Bioinformatics Analysis

Feng

Zhang

Sun

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Purpose. Breast invasive carcinoma (BRCA) is the most common malignant tumor. MiR-124 plays a tumor-suppressive role in human cancer. However, the clinical significance of miR-124 in BRCA remains unclear. The aim of this study was to evaluate the association of hsa-mir-124 expression and the clinicopathological characteristics in BRCA using database analysis. Methods. The clinical data and expression profiles of hsa-mir-124 were obtained from the cancer genome atlas for BRCA (TCGA_BRCA). Then, the prognostic value of hsa-mir-124 in BRCA was investigated using the Cox Regression test, and the association of hsa-mir-124 and pathology TNM stages and pathologic stages were measured by the Kruskal–Wallis test and Wilcox. test. In addition, the association of hsa-mir-124 and tumor molecular phenotypes was performed using the Chi-Square test. Results. We found that the overall survival of patients with high expression of hsa-mir-124-1 and hsa-mir-124-2 was better than that of patients with low expression of hsa-mir-124-1 and hsa-mir-124-2. And the expression of hsa-mir-124-1, hsa-mir-124-2, and hsa-mir-124-3 was mainly enriched in T1/T2 stages, NO/N1 stages, and M0 stages. Then, the expression of hsa-mir-124-1, hsa-mir-124-2, and hsa-mir-124-3 was negatively associated with tumor lymph node metastasis. Moreover, the expression of hsa-mir-124 was associated with tumor molecular phenotype in breast invasive carcinoma. Conclusion. Our findings indicated that hsa-mir-124 expressions were associated with overall survival, TNM stages, pathologic characteristics, and tumor molecular phenotype in BRCA via TCGA_BRCA database, providing a new biomarker and a potential therapeutic target for BRCA patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of the Role of hsa-mir-124 in Predicting Clinical Outcome in Breast Invasive Carcinoma Based on Bioinformatics Analysis

Feng

Zhang

Sun

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…The Rang group's results collectively indicated that miR-542-3p acts as a metastasis suppressor in melanoma [118] and as a tumor suppressor in ovarian cancer by directly targeting CDK14 ) and promoting the proliferation of osteosarcoma cells in vitro [231][232][233]. Furthermore, Haflidadóttir et al reported miR148's dual/opposite role in MITF regulation [84].…”

Section: Mirnamentioning

confidence: 99%

The miRNAs Role in Melanoma and in Its Resistance to Therapy

Varrone

Caputo

2020

IJMS

View full text Add to dashboard Cite

Melanoma is the less common but the most malignant skin cancer. Since the survival rate of melanoma metastasis is about 10–15%, many different studies have been carried out in order to find a more effective treatment. Although the development of target-based therapies and immunotherapeutic strategies has improved chances for patient survival, melanoma treatment still remains a big challenge for oncologists. Here, we collect recent data about the emerging role of melanoma-associated microRNAs (miRNAs) currently available treatments, and their involvement in drug resistance. We also reviewed miRNAs as prognostic factors, because of their chemical stability and resistance to RNase activity, in melanoma progression. Moreover, despite miRNAs being considered small conserved regulators with the limitation of target specificity, we outline the dual role of melanoma-associated miRNAs, as oncogenic and/or tumor suppressive factors, compared to other tumors.

show abstract

“…In contrast, AIT upregulates miR‐126, which is significantly downregulated in a number of tumor types, such as osteosarcoma for which miR‐126 downregulation often appears as sign of poor prognosis (Cheng et al, 2017). miR‐126 is viewed as a tumor suppressor, notably in digestive system cancers where it downregulates various oncogenes (Hu, Xiong, Chen, Zhu, & Zhou, 2019).…”

Section: Regulation Of Mi‐rnas Expression and Functionmentioning

confidence: 99%

Anticancer properties and mechanism of action of the quassinoid ailanthone

Bailly

2020

Phytotherapy Research

View full text Add to dashboard Cite

Ailanthone (AIT) is a quassinoid natural product isolated from the worldwide‐distributed plant Ailanthus altissima. The drug displays multiple pharmacological properties, in particular significant antitumor effects against a variety of cancer cell lines in vitro. Potent in vivo activities have been evidenced in mice bearing hepatocellular carcinoma, nonsmall cell lung cancer and castration‐resistant prostate cancer. This review focusses on the mechanism of action of AIT, notably to highlight the capacity of the drug to activate DNA damage responses, to inhibit the Hsp90 co‐chaperone p23 and to modulate the expression of several microRNA. The interconnexion between these effects is discussed. The unique capacity of AIT to downregulate oncogenic miR‐21 and to upregulate the tumor suppressor miRNAs miR‐126, miR‐148a, miR‐195, and miR‐449a is presented. AIT exploits several microRNAs to exert its anticancer effects in distinct tumor types. AIT is one of the rare antitumor natural products that binds to and strongly inhibits cochaperone p23, opening interesting perspectives to treat cancers. However, the toxicity profile of the molecule may limit its development as an anticancer drug, unless it can be properly formulated to prevent AIT‐induced gastro‐intestinal damages in particular. The antitumor properties of AIT and analogs are underlined, with the aim to encourage further pharmacological studies with this underexplored natural product and related quassinoids. Highlights Ailanthone (AIT) is an anticancer quassinoid isolated from Ailanthus altissima It inhibits proliferation and induces cell death of many cancer cell types The drug activates DNA damage response and targets p23 cochaperone Up or downregulation of several microRNA by AIT contributes to the anticancer activity Analogs or specific formulations must be developed to prevent the toxicity of AIT

show abstract

MicroRNAs with prognostic significance in osteosarcoma: a systemic review and meta-analysis

Cited by 24 publications

References 75 publications

Evaluation of the Role of hsa-mir-124 in Predicting Clinical Outcome in Breast Invasive Carcinoma Based on Bioinformatics Analysis

Evaluation of the Role of hsa-mir-124 in Predicting Clinical Outcome in Breast Invasive Carcinoma Based on Bioinformatics Analysis

The miRNAs Role in Melanoma and in Its Resistance to Therapy

Anticancer properties and mechanism of action of the quassinoid ailanthone

Contact Info

Product

Resources

About